Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Study of the Anti-PDL1 Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid to Investigate Safety and Efficacy of This Combination in Recurrent Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma
Brief Summary: This is a randomized phase II study, aimed at evaluating the efficacy (through progression free survival at 6 months) and safety of 5 different treatments involving atezolizumab, bevacizumab and/or acetylsalicylic acid in advanced recurrent platinum-resistant ovarian cancer patients in order to select the optimal treatments for further development in Phase III.


Options:
A: Arm Label: Arm I (placebo, paclitaxel, carboplatin); Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Placebo, Other: Quality-of-Life Assessment | Arm Label: Arm II (placebo, paclitaxel, carboplatin, bevacizumab); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Carboplatin, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Placebo, Other: Quality-of-Life Assessment | Arm Label: Arm III (paclitaxel, carboplatin, bevacizumab); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Carboplatin, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Quality-of-Life Assessment | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab) | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab)
B: Arm Label: Combination navicixizumab + paclitaxel; Type: EXPERIMENTAL; Interventions: Drug: navicixizumab, Device: Xerna™ TME Panel | Arm Label: Paclitaxel monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Device: Xerna™ TME Panel | Arm Label: Navicixizumab monotherapy; Type: EXPERIMENTAL; Interventions: Drug: navicixizumab, Device: Xerna™ TME Panel | Intervention Type: DRUG; Name: navicixizumab; Assigned to Arm(s): Combination navicixizumab + paclitaxel, Navicixizumab monotherapy | Intervention Type: DEVICE; Name: Xerna™ TME Panel; Assigned to Arm(s): Combination navicixizumab + paclitaxel, Navicixizumab monotherapy, Paclitaxel monotherapy
C: Arm Label: Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab | Arm Label: atezolizumab + bevacizumab + placebo; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: atezolizumab, Drug: placebo | Arm Label: atezolizumab + bevacizumab + acetylsalicylic acid; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: atezolizumab, Drug: acetylsalicylic acid | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab, atezolizumab + bevacizumab + acetylsalicylic acid, atezolizumab + bevacizumab + placebo | Intervention Type: DRUG; Name: atezolizumab; Assigned to Arm(s): atezolizumab + bevacizumab + acetylsalicylic acid, atezolizumab + bevacizumab + placebo | Intervention Type: DRUG; Name: acetylsalicylic acid; Assigned to Arm(s): atezolizumab + bevacizumab + acetylsalicylic acid | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): atezolizumab + bevacizumab + placebo
D: Arm Label: Arm A: Chemotherapy + Bevacizumab + Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Bevacizumab, Drug: Chemotherapy, Drug: Placebos | Arm Label: Arm B: Chemotherapy + Bevacizumab + Atezolizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Atezolizumab, Drug: Chemotherapy | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Arm A: Chemotherapy + Bevacizumab + Placebo, Arm B: Chemotherapy + Bevacizumab + Atezolizumab | Intervention Type: DRUG; Name: Atezolizumab; Assigned to Arm(s): Arm B: Chemotherapy + Bevacizumab + Atezolizumab | Intervention Type: DRUG; Name: Chemotherapy; Assigned to Arm(s): Arm A: Chemotherapy + Bevacizumab + Placebo, Arm B: Chemotherapy + Bevacizumab + Atezolizumab | Intervention Type: DRUG; Name: Placebos; Assigned to Arm(s): Arm A: Chemotherapy + Bevacizumab + Placebo

Answer: C